
ICON Public Limited Company ICLR
$ 109.54
2.55%
Annual report 2024
added 04-04-2026
ICON Public Limited Company Interest Expense 2011-2026 | ICLR
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 337 M | 230 M | 182 M | 13 M | 13.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 337 M | 13 M | 155 M |
Quarterly Interest Expense ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 44.4 M | - | - | - | 2.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.4 M | 2.73 M | 23.6 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioNano Genomics
BNGO
|
5.9 M | $ 1.15 | 1.75 % | $ 6.26 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.07 | 1.39 % | $ 173 M | ||
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
81 M | $ 116.64 | 1.37 % | $ 35.5 B | ||
|
Interpace Biosciences
IDXG
|
-252 K | $ 2.25 | -2.17 % | $ 9.95 M | ||
|
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | ||
|
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
524 K | $ 16.62 | 3.55 % | $ 886 M | ||
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M | ||
|
Myriad Genetics
MYGN
|
800 K | $ 4.6 | 5.63 % | $ 426 M | ||
|
NeoGenomics
NEO
|
296 K | $ 7.92 | 2.99 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
106 K | $ 1.41 | 2.92 % | $ 1.88 M | ||
|
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
1 K | $ 23.04 | -0.39 % | $ 640 M | ||
|
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B | ||
|
Charles River Laboratories International
CRL
|
-22.6 M | $ 179.0 | 1.91 % | $ 8.87 B | ||
|
Senseonics Holdings
SENS
|
-23 K | $ 6.67 | -0.15 % | $ 278 M | ||
|
Medpace Holdings
MEDP
|
-5.34 M | $ 497.33 | 0.77 % | $ 14.3 B | ||
|
Soleno Therapeutics
SLNO
|
110 K | $ 52.63 | - | $ 2.67 B | ||
|
Danaher Corporation
DHR
|
-222 M | $ 193.7 | 2.16 % | $ 138 B | ||
|
Neuronetics
STIM
|
716 K | $ 1.37 | 1.11 % | $ 90.4 M | ||
|
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-292 M | $ 124.59 | 3.03 % | $ 19.8 B | ||
|
Thermo Fisher Scientific
TMO
|
-12 M | $ 508.34 | 2.46 % | $ 192 B | ||
|
Fulgent Genetics
FLGT
|
561 K | $ 15.18 | 5.16 % | $ 459 M | ||
|
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.69 | -3.4 % | $ 61.9 M | ||
|
Guardant Health
GH
|
-10.5 M | $ 80.22 | 2.06 % | $ 10.1 B | ||
|
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
500 K | $ 2.77 | 2.97 % | $ 89.9 K | ||
|
Twist Bioscience Corporation
TWST
|
-903 K | $ 49.97 | 4.3 % | $ 2.99 B | ||
|
Biomerica
BMRA
|
367 | $ 2.07 | -3.5 % | $ 4.75 M | ||
|
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | ||
|
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.5 | 0.67 % | $ 20 B | ||
|
Laboratory Corporation of America Holdings
LH
|
224 M | $ 262.09 | 0.44 % | $ 21.8 B | ||
|
Natera
NTRA
|
9.32 M | $ 199.08 | 3.13 % | $ 19.6 B | ||
|
Celcuity
CELC
|
2.11 M | $ 118.48 | 1.14 % | $ 5.54 B | ||
|
Lantheus Holdings
LNTH
|
31.3 M | $ 81.4 | 1.0 % | $ 5.49 B | ||
|
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K |